RESUMEN
BACKGROUND: Six thoracic pathologists reviewed 259 lung neuroendocrine tumours (LNETs) from the lungNENomics project, with 171 of them having associated survival data. This cohort presents a unique opportunity to assess the strengths and limitations of current World Health Organization (WHO) classification criteria and to evaluate the utility of emerging markers. PATIENTS AND METHODS: Patients were diagnosed based on the 2021 WHO criteria, with atypical carcinoids (ACs) defined by the presence of focal necrosis and/or 2-10 mitoses per 2 mm2. We investigated two markers of tumour proliferation: the Ki-67 index and phospho-histone H3 (PHH3) protein expression, quantified by pathologists and automatically via deep learning. Additionally, an unsupervised deep learning algorithm was trained to uncover previously unnoticed morphological features with diagnostic value. RESULTS: The accuracy in distinguishing typical from ACs is hampered by interobserver variability in mitotic counting and the limitations of morphological criteria in identifying aggressive cases. Our study reveals that different Ki-67 cut-offs can categorise LNETs similarly to current WHO criteria. Counting mitoses in PHH3+ areas does not improve diagnosis, while providing a similar prognostic value to the current criteria. With the advantage of being time efficient, automated assessment of these markers leads to similar conclusions. Lastly, state-of-the-art deep learning modelling does not uncover undisclosed morphological features with diagnostic value. CONCLUSIONS: This study suggests that the mitotic criteria can be complemented by manual or automated assessment of Ki-67 or PHH3 protein expression, but these markers do not significantly improve the prognostic value of the current classification, as the AC group remains highly unspecific for aggressive cases. Therefore, we may have exhausted the potential of morphological features in classifying and prognosticating LNETs. Our study suggests that it might be time to shift the research focus towards investigating molecular markers that could contribute to a more clinically relevant morpho-molecular classification.
Asunto(s)
Neoplasias Pulmonares , Tumores Neuroendocrinos , Humanos , Neoplasias Pulmonares/patología , Neoplasias Pulmonares/clasificación , Tumores Neuroendocrinos/patología , Tumores Neuroendocrinos/clasificación , Femenino , Antígeno Ki-67/metabolismo , Masculino , Biomarcadores de Tumor/metabolismo , Persona de Mediana Edad , Organización Mundial de la Salud , Histonas/metabolismo , Anciano , Pronóstico , Aprendizaje ProfundoRESUMEN
BACKGROUND: This study evaluated the consequences in Europe of the COVID-19 outbreak on pathology laboratories orientated toward the diagnosis of thoracic diseases. MATERIALS AND METHODS: A survey was sent to 71 pathology laboratories from 21 European countries. The questionnaire requested information concerning the organization of biosafety, the clinical and molecular pathology, the biobanking, the workload, the associated research into COVID-19, and the organization of education and training during the COVID-19 crisis, from 15 March to 31 May 2020, compared with the same period in 2019. RESULTS: Questionnaires were returned from 53/71 (75%) laboratories from 18 European countries. The biosafety procedures were heterogeneous. The workload in clinical and molecular pathology decreased dramatically by 31% (range, 3%-55%) and 26% (range, 7%-62%), respectively. According to the professional category, between 28% and 41% of the staff members were not present in the laboratories but did teleworking. A total of 70% of the laboratories developed virtual meetings for the training of residents and junior pathologists. During the period of study, none of the staff members with confirmed COVID-19 became infected as a result of handling samples. CONCLUSIONS: The COVID-19 pandemic has had a strong impact on most of the European pathology laboratories included in this study. Urgent implementation of several changes to the organization of most of these laboratories, notably to better harmonize biosafety procedures, was noted at the onset of the pandemic and maintained in the event of a new wave of infection occurring in Europe.
Asunto(s)
COVID-19/prevención & control , Servicios de Laboratorio Clínico/estadística & datos numéricos , Patología Clínica/estadística & datos numéricos , Patología Molecular/estadística & datos numéricos , Encuestas y Cuestionarios , Enfermedades Torácicas/diagnóstico , Bancos de Muestras Biológicas/organización & administración , Bancos de Muestras Biológicas/estadística & datos numéricos , COVID-19/epidemiología , COVID-19/virología , Servicios de Laboratorio Clínico/tendencias , Contención de Riesgos Biológicos/estadística & datos numéricos , Brotes de Enfermedades , Europa (Continente)/epidemiología , Predicción , Humanos , Pandemias , Patología Clínica/métodos , Patología Clínica/tendencias , Patología Molecular/métodos , Patología Molecular/tendencias , SARS-CoV-2/aislamiento & purificación , SARS-CoV-2/fisiología , Manejo de Especímenes/métodos , Manejo de Especímenes/estadística & datos numéricos , Enfermedades Torácicas/terapiaRESUMEN
The worldwide incidence of pulmonary carcinoids is increasing, but little is known about their molecular characteristics. Through machine learning and multi-omics factor analysis, we compare and contrast the genomic profiles of 116 pulmonary carcinoids (including 35 atypical), 75 large-cell neuroendocrine carcinomas (LCNEC), and 66 small-cell lung cancers. Here we report that the integrative analyses on 257 lung neuroendocrine neoplasms stratify atypical carcinoids into two prognostic groups with a 10-year overall survival of 88% and 27%, respectively. We identify therapeutically relevant molecular groups of pulmonary carcinoids, suggesting DLL3 and the immune system as candidate therapeutic targets; we confirm the value of OTP expression levels for the prognosis and diagnosis of these diseases, and we unveil the group of supra-carcinoids. This group comprises samples with carcinoid-like morphology yet the molecular and clinical features of the deadly LCNEC, further supporting the previously proposed molecular link between the low- and high-grade lung neuroendocrine neoplasms.
Asunto(s)
Biomarcadores de Tumor/genética , Tumor Carcinoide/genética , Carcinoma de Células Grandes/genética , Neoplasias Pulmonares/genética , Carcinoma Pulmonar de Células Pequeñas/genética , Adolescente , Adulto , Anciano , Anciano de 80 o más Años , Tumor Carcinoide/mortalidad , Tumor Carcinoide/patología , Carcinoma de Células Grandes/mortalidad , Carcinoma de Células Grandes/patología , Hibridación Genómica Comparativa , Conjuntos de Datos como Asunto , Femenino , Genómica , Proteínas de Homeodominio/genética , Humanos , Péptidos y Proteínas de Señalización Intracelular/genética , Pulmón/patología , Neoplasias Pulmonares/mortalidad , Neoplasias Pulmonares/patología , Aprendizaje Automático , Masculino , Proteínas de la Membrana/genética , Persona de Mediana Edad , Proteínas del Tejido Nervioso/genética , Pronóstico , Carcinoma Pulmonar de Células Pequeñas/mortalidad , Carcinoma Pulmonar de Células Pequeñas/patología , Tasa de Supervivencia , Adulto JovenRESUMEN
Ectopic thymic tissue outside its core position in the antero-superior mediastinum is quite common owing to the complexity of embryonal thymus development, whereby reported prevalence values (1 to 90%) are heavily dependent on the method of investigation and the intensity of the workup. The debated prevalence and relevance of ectopic thymic tissue and its accessibility underlie the ongoing discussion whether modern, minimally invasive thymectomy strategies can match the proven benefit of the radical transsternal thymectomy procedure for the treatment of Myasthenia gravis. In this context, the following article covers the etiology, prevalence, and location of normal-looking, reactive, and neoplastic ectopic thymic tissue. Furthermore, ectopic tissues and tumors inside or adjacent to the thymus are mentioned.
Asunto(s)
Coristoma , Miastenia Gravis , Neoplasias del Timo , Humanos , Timectomía , TimoRESUMEN
BACKGROUND: Thymic epithelial tumours are rare cancers for which new treatment options are required. Identification of putative predictive markers is important for developing clinical trials. We studied the expression of five putative predictive biomarkers, potentially actionable by approved experimental drugs. METHODS: CD52, CD22, CD26, EG5, and IGF-1R expression were investigated by immunohistochemistry in formalin-fixed surgical samples of thymic epithelial tumour patients. All samples containing 10% positive epithelial tumour cells, independent of tumour cell intensity, were considered as positive. Correlation with histological subtype was performed. RESULTS: 106 surgical samples (89 thymomas, 12 thymic carcinoma, and 5 thymic neuroendocrine tumours) were evaluated. Overall, CD52, CD22, CD26, EG5 and IGF-1R expression was observed in 7%, 42%, 25%, 42% and 77% of samples, respectively. CD52 expression was more frequent in B2 and B3 thymoma. All TET subtypes stained for CD22, mainly AB thymoma (68%). CD26 expression also correlated with AB thymoma (68%), and A thymoma (50%) subtype, while IGFR1 was the most common marker expressed by thymic carcinoma samples (92%), followed by EG5 (60%). Only EG5 expression was significantly higher in thymic carcinomas than in thymomas (75% vs. 38%, p=0.026). CONCLUSIONS: Our data were consistent with a previous study of IGF-1R expression. Based on their expression, activity of agents targeting CD52, CD 22, CD26 and EG5 could be further explored in TET patients.
Asunto(s)
Antígeno CD52/metabolismo , Dipeptidil Peptidasa 4/metabolismo , Cinesinas/metabolismo , Receptores de Somatomedina/metabolismo , Lectina 2 Similar a Ig de Unión al Ácido Siálico/metabolismo , Neoplasias del Timo/metabolismo , Biomarcadores , Biomarcadores de Tumor , Antígeno CD52/genética , Dipeptidil Peptidasa 4/genética , Femenino , Expresión Génica , Humanos , Inmunohistoquímica , Cinesinas/genética , Masculino , Pronóstico , Transporte de Proteínas , Receptor IGF Tipo 1 , Receptores de Somatomedina/genética , Lectina 2 Similar a Ig de Unión al Ácido Siálico/genética , Neoplasias del Timo/genética , Neoplasias del Timo/mortalidad , Neoplasias del Timo/patologíaRESUMEN
Though most paragangliomas arise as sporadic tumors, the recent advantages in the genetic screening revealed that about 30 % of paragangliomas are linked to hereditary mutations, such as those involving SDH genes. A 22-year-old woman carrying a left main bronchus tumor underwent surgery in our institution. Her past medical history included a GIST without KIT or PDGFRA mutation. The histological examination revealed a nested proliferation of medium-sized cells expressing neuroendocrine markers (chromogranin A and synaptophysin). The neoplastic cells failed to express SDHB gene product. These findings led us to the final diagnosis of bronchial paraganglioma in the setting of Carney-Stratakis syndrome. Bronchial paragangliomas are exceedingly rare tumors with polymorphous clinical presentation, and usually benign clinical course. Though most paragangliomas are sporadic, some tumors are associated with specific hereditary disease, especially those occurring in young patients or in combination with other neoplasms.
Asunto(s)
Neoplasias de los Bronquios/genética , Tumores del Estroma Gastrointestinal/complicaciones , Paraganglioma Extraadrenal/genética , Paraganglioma/complicaciones , Succinato Deshidrogenasa/deficiencia , Femenino , Tumores del Estroma Gastrointestinal/genética , Humanos , Paraganglioma/genética , Succinato Deshidrogenasa/genética , Adulto JovenRESUMEN
INTRODUCTION: Pulmonary artery sarcoma is a rare disease with non-specific symptoms. The clinical and radiological presentation can mimic pulmonary embolism with chronic thromboembolic pulmonary hypertension. Management is essentially surgical but the prognosis remains poor. CASE REPORT: A patient presented with symptoms of pulmonary embolism. Despite vitamin K antagonist therapy, he suffered from extension of the endovascular defects and his pulmonary hypertension increased. Suspicious results of positron emission tomography suggested the diagnosis of pulmonary artery sarcoma that was confirmed by surgery. However, the outcome was unfavourable, leading to death of the patient. CONCLUSION: This case reinforces the idea that the clinical and tomodensitometric presentations of pulmonary arterial sarcoma and chronic thromboembolic pulmonary hypertension are similar. The positron emission tomography seems to be a key to distinguishing these two diagnoses.
Asunto(s)
Hemangiosarcoma/diagnóstico , Neoplasias Pulmonares/diagnóstico , Arteria Pulmonar/patología , Embolia Pulmonar/diagnóstico , Anciano , Diagnóstico Diferencial , Hemangiosarcoma/complicaciones , Humanos , Hipertensión Pulmonar/diagnóstico , Hipertensión Pulmonar/etiología , Neoplasias Pulmonares/complicaciones , Neoplasias Pulmonares/patología , MasculinoRESUMEN
PURPOSE: We report the results of a French multicenter retrospective study based on a period of more than 30 years and a review of the literature in order to more clearly define the surgical approach and specific pediatric risk factors. METHODS: Clinical data of children comprising all histologic subtypes of thymic epithelial tumors (TET) treated between 1979 and 2009 in French pediatric oncology centers were retrospectively analyzed and discussed in the light of a review of all pediatric cases reported in the literature. RESULTS: Nine cases were identified, corresponding to five females and four males with a median age of 13 years (range: 7.5-17). Histologic subtypes were type AB (n = 1), type B (n = 5) and type C (n = 3). Treatment consisted of tumor resection (4 R0, 4 R1, 1 R2) via right anterior thoracotomy, posterolateral thoracotomy, left thoracoscopy, sternotomy and cervicosternotomy, and/or chemotherapy, mainly cyclophosphamide-doxorubicin-cisplatin (CAP; n = 5), and/or radiotherapy (n = 4). Two patients with TET type C died. All other patients are alive with a median follow-up of 4 years (range: 1.5-20). Review of a total of 93 pediatric cases reported in the literature showed statistically significant associations between less favorable histologic subtypes and male gender (P = 0.012), advanced Masaoka stage (P < 0.001) and quality of resection (P < 0.001) respectively. CONCLUSIONS: A review of the literature and our series identified several risk factors to take into account in the therapeutically decision. Complete resection through a sternotomy is highly recommended.
Asunto(s)
Neoplasias Glandulares y Epiteliales/cirugía , Neoplasias del Timo/cirugía , Adolescente , Niño , Femenino , Humanos , Masculino , Estadificación de Neoplasias , Neoplasias Glandulares y Epiteliales/patología , Neoplasias del Timo/patologíaAsunto(s)
Carcinoma/patología , Timoma/patología , Neoplasias del Timo/patología , Antígenos CD/análisis , Biomarcadores de Tumor , Carcinoma/química , Cromograninas/análisis , Humanos , Queratinas/análisis , Proteínas de Neoplasias/análisis , Estadificación de Neoplasias , Timoma/química , Timoma/clasificación , Neoplasias del Timo/químicaRESUMEN
Inhibition of tumour necrosis factor-alpha (TNF-alpha), levels of which are increased in the blood of cirrhotic rats, prevents hyperdynamic circulatory state, mainly by decreasing the vascular overproduction of nitric oxide. Hepatopulmonary syndrome, which is characterised by intrapulmonary vascular dilatation and increased alveolar to arterial oxygen tension difference (PA-a,O2), is mainly related to pulmonary over-production of NO by macrophages accumulated in lung vessels. Since TNF-alpha is a potent activator of macrophagic inducible nitric oxide synthase (NOS), the aim of this study was to investigate whether TNF-alpha inhibition prevented hepatopulmonary syndrome and hyperdynamic circulatory state in rats with cirrhosis. TNF-alpha was inhibited by 5 weeks of pentoxifylline (10 mg x kg body weigh(-1) x day(-1)) in rats with cirrhosis induced by common bile duct ligation. Cardiac output, pulmonary and systemic vascular resistance, PA-a,O2 and cerebral uptake of intravenous technetium-99m-labelled albumin macroaggregates (which reflects intrapulmonary vascular dilatation) were similar in sham- and pentoxifylline-treated cirrhotic rats. Blood TNF-alpha concentrations and pulmonary intravascular macrophage sequestration, as assessed by morphometric analysis and radioactive colloid uptake, were decreased with pentoxifylline. Pentoxifylline also prevented increases in aorta and lung NOS activities and inducible NOS expression. Thus pentoxifylline prevents development of hyperdynamic circulatory state and hepatopulmonary syndrome, probably by inhibiting the effects of tumour necrosis factor-alpha on vascular nitric oxide synthase and intravascular macrophages. These results support an important role for tumour necrosis factor-alpha in the genesis of hepatopulmonary syndrome.
Asunto(s)
Inhibidores Enzimáticos/farmacología , Síndrome Hepatopulmonar/prevención & control , Cirrosis Hepática/fisiopatología , Pentoxifilina/farmacología , Factor de Necrosis Tumoral alfa/antagonistas & inhibidores , Animales , Aorta/enzimología , Traslocación Bacteriana/efectos de los fármacos , Células Sanguíneas/patología , Circulación Sanguínea/efectos de los fármacos , Hemodinámica/efectos de los fármacos , Cirrosis Hepática/sangre , Cirrosis Hepática/metabolismo , Cirrosis Hepática/microbiología , Pulmón/enzimología , Macrófagos/patología , Masculino , Óxido Nítrico Sintasa/antagonistas & inhibidores , Óxido Nítrico Sintasa/metabolismo , Fagocitosis , Circulación Pulmonar/efectos de los fármacos , Ratas , Ratas Wistar , Factor de Necrosis Tumoral alfa/metabolismoRESUMEN
We report a case of pulmonary carcinosarcoma with jejunal metastasis. The lung is an exceptional localization for carcinosarcoma, a tumor with carcinomatous and sarcomatous components. These two components are closely related but well-defined morphologically and immunohistochemically. Risk of metastasis and local recurrence is high. Surgery is the treatment of choice for localized forms. Prognosis depends on the sarcomatous component which is usually sensitive to chemotherapy, with at least doxorubicin and ifosfamide. This rare case illustrates the potential for jejunal metastasis and complete response to chemotherapy, proven histologically at 33 months.
Asunto(s)
Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Carcinosarcoma/tratamiento farmacológico , Neoplasias del Yeyuno/tratamiento farmacológico , Neoplasias Pulmonares , Carcinosarcoma/diagnóstico , Carcinosarcoma/secundario , Cisplatino/administración & dosificación , Doxorrubicina/administración & dosificación , Humanos , Ifosfamida/administración & dosificación , Neoplasias del Yeyuno/diagnóstico , Neoplasias del Yeyuno/secundario , Masculino , Persona de Mediana Edad , Resultado del TratamientoRESUMEN
Cardiac fibroma and inflammatory myofibroblastic tumor (IMT) of the heart are rare lesions occurring in young patients and having pathologic similarities. We compared the morphologic and immunohistochemical features of seven cardiac fibromas, including one biopsied at birth and removed 4 years later, and two IMTs of the heart diagnosed at Marie Lannelongue Surgical Center (Le Plessis Robinson, France) between 1980 and 1999. Cardiac fibromas occurred in five females and two males and were surgically biopsied (n = 2) or removed (n = 6) between the ages of 8 days to 31 years (mean 7 +/- 12 years). Inflammatory myofibroblastic tumors were removed in two male patients, aged 13 weeks and 1 year, both alive and well 9 months and 5 years after surgery, respectively. Fibromas were ventricular lesions measuring 3 to 10 cm (mean, 5.7 +/- 2.2 cm). They contained entrapped myocytes and wavy elastic fibers. Three cases contained calcifications. Spindle cells were monomorphic. Their nucleus had a thin chromatin without nucleolus. Mitoses and extramedullary hematopoiesis were only observed in fibromas from patients younger than 5 months (n = 5) while prominent collagen fibrosis was present in fibromas from patients older than 4 years (n = 3). Inflammatory myofibroblastic tumors were endocardial lesions measuring 2 and 2.5 cm. They were covered by fibrin. Spindle cells were larger than in fibromas. Their nucleus had obvious nucleoli. They were associated with numerous inflammatory cells in a variable amount of myxoid background. Occasional mitoses and foci of necrosis were present. Spindle cells in both fibromas and IMTs strongly expressed smooth-muscle actin and were negative for desmin, CD34, S-100 protein, and p53. Our study shows that IMT must be considered in the differential diagnosis of cardiac fibroma especially in cases of inflammatory syndrome, location outside the ventricular myocardium, or multinodular lesions. Morphologic analysis permits the correct diagnosis, while immunochemistry shows a myofibroblastic differentiation in both lesions.
Asunto(s)
Fibroma/patología , Granuloma de Células Plasmáticas/patología , Neoplasias Cardíacas/patología , Adulto , Biomarcadores de Tumor/análisis , Preescolar , Endocardio/patología , Femenino , Fibroma/química , Fibroma/cirugía , Granuloma de Células Plasmáticas/metabolismo , Granuloma de Células Plasmáticas/cirugía , Neoplasias Cardíacas/química , Neoplasias Cardíacas/cirugía , Ventrículos Cardíacos/química , Ventrículos Cardíacos/metabolismo , Hematopoyesis Extramedular , Humanos , Técnicas para Inmunoenzimas , Lactante , Recién Nacido , Masculino , Miocardio/química , Miocardio/patología , Miofibromatosis/patología , Proteínas de Neoplasias/análisisRESUMEN
1. To characterize the prostanoid receptors (TP, FP, EP(1) and/or EP(3)) involved in the vasoconstriction of human pulmonary veins, isolated venous preparations were challenged with different prostanoid-receptor agonists in the absence or presence of selective antagonists. 2. The stable thromboxane A(2) mimetic, U46619, was a potent constrictor agonist on human pulmonary veins (pEC(50)=8.60+/-0.11 and E(max)=4.61+/-0.46 g; n=15). The affinity values for two selective TP-antagonists (BAY u3405 and GR32191B) versus U46619 were BAY u3405: pA(2)=8.94+/-0.23 (n=3) and GR32191B: apparent pK(B)=8.25+/-0.34 (n=3), respectively. These results are consistent with the involvement of TP-receptor in the U46619 induced contractions. 3. The two EP(1)-/EP(3)- agonists (17-phenyl-PGE(2) and sulprostone) induced contraction of human pumonary veins (pEC(50)=8.56+/-0.18; E(max)=0.56+/-0.24 g; n=5 and pEC(50)=7.65+/-0.13; E(max)=1.10+/-0.12 g; n=14, respectively). The potency ranking for these agonists: 17-phenyl-PGE(2) > sulprostone suggests the involvement of an EP(1)-receptor rather than EP(3). In addition, the contractions induced by sulprostone, 17-phenyl-PGE(2) and the IP-/EP(1)- agonist (iloprost) were blocked by the DP-/EP(1)-/EP(2)-receptor antagonist (AH6809) as well as by the EP(1) antagonist (SC19220). 4. PGF(2alpha) induced small contractions which were blocked by AH6809 while fluprostenol was ineffective. These results indicate that FP-receptors are not implicated in the contraction of human pulmonary veins. 5. These data suggest that the contractions induced by prostanoids involved TP- and EP(1)-receptors in human pulmonary venous smooth muscle.
Asunto(s)
Dinoprostona/análogos & derivados , Venas Pulmonares/fisiología , Receptores de Prostaglandina E/fisiología , Receptores de Tromboxanos/fisiología , Vasoconstricción , Xantonas , Ácido 15-Hidroxi-11 alfa,9 alfa-(epoximetano)prosta-5,13-dienoico/farmacología , Compuestos de Bifenilo/farmacología , Carbazoles/farmacología , Técnicas de Cultivo , Ácido Dibenzo(b,f)(1,4)oxazepina-10(11H)-carboxílico, 8-cloro-, 2-acetilhidrazida/farmacología , Dinoprostona/farmacología , Relación Dosis-Respuesta a Droga , Endotelio Vascular/fisiología , Femenino , Ácidos Heptanoicos/farmacología , Humanos , Iloprost/farmacología , Masculino , Persona de Mediana Edad , Contracción Muscular/efectos de los fármacos , Músculo Liso Vascular/efectos de los fármacos , Músculo Liso Vascular/fisiología , Antagonistas de Prostaglandina/farmacología , Prostaglandinas F Sintéticas/farmacología , Venas Pulmonares/efectos de los fármacos , Receptores de Prostaglandina/fisiología , Receptores de Prostaglandina E/agonistas , Receptores de Prostaglandina E/antagonistas & inhibidores , Subtipo EP1 de Receptores de Prostaglandina E , Subtipo EP3 de Receptores de Prostaglandina E , Receptores de Tromboxanos/antagonistas & inhibidores , Sulfonamidas/farmacología , Vasoconstricción/efectos de los fármacos , Xantenos/farmacologíaRESUMEN
BACKGROUND: Increased secretion of mucus is a hallmark of many respiratory diseases and contributes significantly to the airflow limitation experienced by many patients. While the current pharmacological approach to reducing mucus and sputum production in patients is limited, clinical studies have suggested that drugs which inhibit the cyclooxygenase and/or 5-lipoxygenase enzymatic pathways may reduce secretory activity in patients with airway disease. AIM: This study was performed to investigate the effects of indomethacin (cyclooxygenase inhibitor) and Bay x 1005 (5-lipoxygenase inhibitor) on MUC5AC release from human airways in vitro. METHODS: An immunoradiometric assay was used to determine the quantities of MUC5AC present in the biological fluids derived from human airways in vitro. The measurements were made with a mixture of eight monoclonal antibodies (MAbs; PM8) of which the 21 M1 MAb recognized a recombinant M1 mucin partially encoded by the MUC5AC gene. RESULTS: The quantities of MUC5AC detected in the biological fluids derived from human bronchial preparations were not modified after treatment with indomethacin (cyclooxygenase inhibitor) and/or an inhibitor of the 5-lipoxygenase metabolic pathway (BAY x 1005). CONCLUSION: These results suggest that the cyclooxygenase and 5-lipoxygenase metabolic pathways play little or no role in the release of MUC5AC from human airways.
Asunto(s)
Bronquios/metabolismo , Indometacina/farmacología , Mucinas/metabolismo , Quinolinas/farmacología , Antiinflamatorios no Esteroideos/farmacología , Inhibidores de la Ciclooxigenasa/farmacología , Humanos , Técnicas In Vitro , Inhibidores de la Lipooxigenasa , Mucina 5ACRESUMEN
OBJECTIVES: Cholesterol crystal embolism is a severe complication of atherosclerosis responsible for nonspecific cutaneous, renal, and, less often, digestive manifestations that may mimic other systemic diseases. METHODS: We reviewed retrospectively 10 patients with histologically proven cholesterol crystal emboli diagnosed by endoscopic GI biopsy. RESULTS: All patients had prior clinical manifestations of severe atherosclerosis and predisposing factors for cholesterol migration. They all had cutaneous manifestations of cholesterol crystal embolism, acute renal failure, and biological inflammatory syndrome. Digestive symptoms were found in the 10 patients: abdominal pain in eight, diarrhea in four, and GI bleeding in three. GI endoscopy ruled out specific digestive diseases, showing only a congestive or erosive mucosa. Histological diagnosis of cholesterol crystal emboli was based on gastric biopsy in nine patients, duodenal biopsy in four, colonic biopsy in three, and rectal biopsy in one, with six having positive biopsies on multiple sites. Outcome after the diagnosis of cholesterol crystal embolism was poor, with all patients requiring permanent hemodialysis. Death by atherosclerosis complications occurred in five patients. CONCLUSIONS: This cohort suggests that upper GI endoscopy may be helpful in demonstrating the presence of cholesterol crystal embolism, and that diagnosis of cholesterol crystal emboli on digestive tract biopsy indicates advanced systemic atherosclerosis disease of poor prognosis.
Asunto(s)
Sistema Digestivo/patología , Embolia por Colesterol/patología , Lesión Renal Aguda/etiología , Anciano , Anciano de 80 o más Años , Arteriosclerosis/complicaciones , Arteriosclerosis/fisiopatología , Biopsia , Colesterol/química , Estudios de Cohortes , Cristalización , Embolia por Colesterol/etiología , Femenino , Enfermedades Gastrointestinales/etiología , Humanos , Inflamación/etiología , Masculino , Persona de Mediana Edad , Estudios Retrospectivos , Análisis de Supervivencia , SíndromeRESUMEN
The contractile response to cysteinyl-leukotrienes was studied in isolated human pulmonary arterial rings. Concentration-response curves for leukotriene C(4) were significantly potentiated by the cyclooxygenase inhibitor indomethacin (1.7 microM) and after endothelial denudation. Measurements of 6-keto prostaglandin F(1alpha) showed that cysteinyl-leukotrienes stimulated the release of prostacyclin. A single concentration (1 microM) of either leukotriene C(4) or leukotriene D(4) resulted in both contraction and relaxation. Indomethacin abolished the relaxant phase and enhanced the amplitude of the contraction, supporting that cysteinyl-leukotriene-induced contractions of the human pulmonary artery may be functionally antagonised by the release of prostacyclin. The contractions induced by leukotriene C(4) were resistant to the two cysteinyl-leukotriene receptor antagonists MK 571 ((3-(-2(7-chloro-2-quinolinyl)ethenyl)phenyl)((3-(dimethylamino-3-oxo propyl)thio)methyl)thio propanoic acid, 1 microM) and BAY u9773 (6(R)-(4'-carboxyphenylthio)-5(S)-hydroxy-7(E),9(E), 11(Z)14(Z)-eicosatetrenoic acid, 3 microM), both in the absence and presence of indomethacin. These findings suggest a functional cysteinyl-leukotriene receptor in the human pulmonary artery with antagonist properties not previously described in human tissue.
Asunto(s)
Cisteína/farmacología , Epoprostenol/metabolismo , Leucotrienos/farmacología , Proteínas de la Membrana , Arteria Pulmonar/efectos de los fármacos , Vasoconstricción/efectos de los fármacos , 6-Cetoprostaglandina F1 alfa/metabolismo , Relación Dosis-Respuesta a Droga , Endotelio Vascular/fisiología , Femenino , Humanos , Técnicas In Vitro , Indometacina/farmacología , Antagonistas de Leucotrieno/farmacología , Leucotrieno C4/farmacología , Leucotrieno D4/farmacología , Masculino , Persona de Mediana Edad , Propionatos/farmacología , Arteria Pulmonar/metabolismo , Arteria Pulmonar/fisiología , Quinolinas/farmacología , Receptores de Leucotrienos/fisiología , SRS-A/análogos & derivados , SRS-A/farmacologíaRESUMEN
A 36-year-old man presented with a pleural tumor. The first pathologic analysis diagnosed biphasic pleural malignant mesothelioma. However, the atypical clinical course, the early development of lung metastases and a new reading of histologic documents led to the diagnosis of primary pleural synovial sarcoma. The literature review is limited, as only nine other cases have been reported to date. Chest pain is the only constant clinical feature. Misleading interpretation of histologic material is frequent (6 of 10 cases). Only a complete immuno-histochemical study confronted with the clinical course can lead to the correct diagnosis. Because the efficacy of chemotherapy and/or radiotherapy is poor, surgery remains the basis of treatment, whenever possible. Evolution is mainly intra-thoracic, with multiple local recurrences and lung metastases. Prognostic is poor, a survival rate is similar to that of primary pulmonary sarcomas.
Asunto(s)
Neoplasias Pleurales/patología , Sarcoma Sinovial/patología , Adulto , Diagnóstico Diferencial , Humanos , Inmunohistoquímica , Neoplasias Pulmonares/secundario , Masculino , Mesotelioma/patología , Recurrencia Local de Neoplasia/patología , Neoplasias Pleurales/cirugía , Pronóstico , Sarcoma Sinovial/secundario , Sarcoma Sinovial/cirugía , Tasa de Supervivencia , Resultado del TratamientoRESUMEN
BACKGROUND: Long congenital tracheal stenosis is a life-threatening condition, and the available surgical treatments do not give satisfactory long-term results. METHODS: Human embryonic tracheas were implanted in the abdominal cavities of nude mice until their differentiation was completed. These differentiated tracheas were used to patch-repair surgically induced tracheal stenosis in piglets. The human, mouse, or pig origin, of all the cells in the two successive xenotransplants in the nude mouse and the pig, was determined on tissue sections by in situ hybridization with species-specific DNA probes. RESULTS: The transplanted pigs thrived and reached normal adulthood, irrespective of the administration of immunosuppressive treatment. The human tracheal tissue developed in nude mice conserved human structures, with the exception of feeding capillaries, which were of mouse origin. The tracheal patch in the adult healthy pigs comprised only pig cells organized into a fibrous scar, which was covered by normal pig epithelium. CONCLUSIONS: Results suggest that human embryonic trachea grown in nude mice can be successfully used as patch tracheoplasty for long congenital tracheal stenosis without conventional immunosuppression.
Asunto(s)
Tráquea/embriología , Estenosis Traqueal/congénito , Estenosis Traqueal/cirugía , Trasplante Heterólogo , Animales , Sondas de ADN/análisis , Humanos , Hibridación Fluorescente in Situ , Ratones , Ratones Endogámicos BALB C , Ratones Desnudos , Porcinos , Tráquea/trasplanteRESUMEN
BACKGROUND: Chronic airway diseases are often associated with marked mucus production, however, little is known about the regulation of secretory activity by locally released endogenous mediators. AIM: This investigation was performed to determine the release of MUC5AC mucin from human bronchial preparations using the purinergic agonists adenosine 5'-triphosphate (ATP) and uridine 5'-triphosphate (UTP). METHODS: Immunohistochemical and immunoradiometric assays (IRMA) were used to detect the MUC5AC mucin. Immunohistochemical analysis were performed using individual 1-13 M1 and 21 M1 MAbs recognizing a recombinant M1 mucin partially encoded by the MUC5AC gene. IRMA measurments were performed using a mixture of eight anti-M1 mucin MAbs (PM8), which included both 1-13 M1 and 21 M1 MAbs. Lysozyme and protein were also measured in the biological fluids derived from human bronchial preparations obtained from patients who had undergone surgery for lung carcinoma. RESULTS: The anti-M1 monoclonal antibodies labelled epithelial goblet cells. After challenge of human bronchial preparations with ATP, the goblet cells exhibited less staining. In contrast, UTP did not alter the immunolabelling of goblet cells. MUC5AC mucin in the bronchial fluids derived from ATP-challenged preparations was increased while UTP had no effect on release. ATP did not alter either the quantities of lysozyme or protein detected in the biological fluids. CONCLUSION: These results suggest that ATP may regulate epithelial goblet cell secretion of MUC5AC mucin from human airways in vitro.
Asunto(s)
Adenosina Trifosfato/metabolismo , Bronquios/metabolismo , Mucinas/metabolismo , Agonistas Purinérgicos , Adenosina Trifosfato/farmacología , Bronquios/efectos de los fármacos , Bronquios/patología , Técnicas de Cultivo , Humanos , Técnicas para Inmunoenzimas , Mucina 5AC , Muramidasa/metabolismo , Biosíntesis de Proteínas , Uridina Trifosfato/metabolismo , Uridina Trifosfato/farmacologíaRESUMEN
Three years after four cycles of bleomycin, etoposide, and cisplatin (BEP) chemotherapy for a nonseminomatous germ-cell tumor of the mediastinum followed by complete resection of residual teratoma in a 21-year-old man, a mediastinal recurrence was diagnosed as an extraskeletal osteosarcoma. After unsuccessful chemotherapy and removal of the tumor, the patient died of cerebral metastases. Histologic transformation of the teratomatous components of nonseminomatous germ-cell tumors is an uncommon phenomenon showing a particular aspect of germ-cell tumor biology. We review the literature and discuss the pathogenesis concerning this subject.